New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
AUTOR(ES)
Lin, Nancy U
FONTE
BioMed Central
RESUMO
Over the past several years many advances have been made in our understanding of critical pathways involved in carcinogenesis and tumor growth. These advances have led to the investigation of small molecule inhibitors of the ErbB family of receptor tyrosine kinases across a broad spectrum of malignancies. In this article we summarize the rationale for targeting members of the ErbB family in breast cancer, and review the preclinical and clinical data for the agents that are furthest in development. In addition, we highlight directions for future research, such as exploration of the potential crosstalk between the ErbB and hormone receptor signal transduction pathways, identification of predictive markers for tumor sensitivity, and development of rational combination regimens that include the tyrosine kinase inhibitors.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549180Documentos Relacionados
- New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
- Tyrosine kinase signalling in breast cancer: Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer
- Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
- Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates
- Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer